ALIBABA PAYS $600M TO SETTLE US DRUG PROBE

The Justice Department announced the settlement with the Chinese tech giant and its payment partner for their alleged failure to implement adequate safeguards against unlawful drug transactions on their platforms. The investigation centered on whether the companies took sufficient steps to prevent the sale and importation of illegal pharmaceuticals and controlled substances through their services. Federal authorities determined the firms did not maintain proper compliance measures to detect and block such activities. The $600 million settlement represents one of the largest penalties against a major Chinese technology company for compliance violations. Both Alibaba and its payment processor must now implement enhanced monitoring systems and reporting procedures going forward. This resolution closes a significant legal matter for Alibaba as it navigates increased US regulatory scrutiny of Chinese tech companies. The settlement demonstrates the Justice Department's commitment to holding major platforms accountable for third-party activities conducted on their networks.